Ann Lab Med.  2013 Jan;33(1):28-33. 10.3343/alm.2013.33.1.28.

Prevalence of p16 Methylation and Prognostic Factors in Plasma Cell Myeloma at a Single Institution in Korea

• Kim H
• Jekarl DW
• Kim M
• Kim Y
• Lim J
• Han K
• Min CK

• KMID: 1781294
• DOI: http://doi.org/10.3343/alm.2013.33.1.28

Abstract

BACKGROUND
The primary purpose of this study was to investigate the prevalence and characteristics of p16 methylation and determine the prognostic implications of the clinical data, hematologic data, and p16 methylation changes in plasma cell myeloma (PCM).
METHODS
We reviewed clinical characteristics and results of laboratory tests and investigated the response to combination chemotherapy and survival time. DNA methylation of the p16 gene was tested by methylation-specific PCR. Clinical significance was evaluated.
RESULTS
A total of 103 patients were enrolled in this study. The median patient age was 59.0 yr at diagnosis and the male to female ratio was 1.15:1. According to the International Staging System (ISS), patients were diagnosed as stage: I (N=17, 16.5%), II (N=41, 39.8%), III (N=39, 37.9%), or not classified (N=6). Forty-five (43.7%) patients and 36 (35.0%) patients showed abnormal karyotype and complex karyotype, respectively, on the chromosome study. The p16 methylation was observed in 39 (37.9%) of 103 patients, but there was no significant association between p16 methylation status and other clinical or laboratory factors and survival outcome. Male gender, albumin, and complex karyotype were independent prognostic factors for overall survival according to multivariate analysis (P<0.05).
CONCLUSIONS
The male gender, low serum albumin level, and complex karyotype were independent poor prognostic factors for PCM. p16 methylation was relatively common in PCM, but did not influence the survival outcome.

Keyword

Myeloma; p16; Methylation; Prognosis

MeSH Terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents/therapeutic use
Cyclin-Dependent Kinase Inhibitor p16/*genetics
*DNA Methylation
Female
Humans
Karyotyping
Male
Middle Aged
Multiple Myeloma/drug therapy/*genetics/mortality
Neoplasm Staging
Polymerase Chain Reaction
Prognosis
Republic of Korea
Serum Albumin/analysis
Sex Factors
Survival Rate
Antineoplastic Agents
Cyclin-Dependent Kinase Inhibitor p16
Serum Albumin

Figure

• 

  Fig. 1 Survival curves according to the International Staging System (A) and Durie-Salmon Stage (B) of patients with plasma cell myeloma.

Reference

1. Ries LAG MD KM, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK, editors. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute;http://seer.cancer.gov/csr/1975_2005/(based on November 2007 SEER data submission, posted to the SEER web site 2008).

2. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. Plasma cell neoplasm. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008. 4th ed. Lyon: IARC;p. 200–213.

3. Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica. 2009; 94:270–275. PMID: 19144659.

4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58:71–96. PMID: 18287387.

5. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007; 109:3489–3495. PMID: 17209057.

6. Bladé J, Rosiñol L, Cibeira MT. Prognostic factors for multiple myeloma in the era of novel agents. Ann Oncol. 2008; 19(Suppl 7):vii117–vii120. PMID: 18790932.

7. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Group Français de Cytogénétique Hématologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001; 98:2229–2238. PMID: 11568011.

8. Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, et al. Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood. 2007; 109:1228–1232. PMID: 16840723.

9. Goto T, Mizukami H, Shirahata A, Sakata M, Saito M, Ishibashi K, et al. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Anticancer Res. 2009; 29:275–277. PMID: 19331161.

10. Ohashi H, Tsushita K, Utsumi M, Shimoyama M, Murate T, Uchida T, et al. Relationship between methylation of the p15 gene and ectopic expression of the EVI-1 gene in myelodysplastic syndromes (MDS). Leukemia. 2001; 15:990–991. PMID: 11417490.

11. Guillerm G, Gyan E, Wolowiec D, Facon T, Avet-Loiseau H, Kuliczkowski K, et al. p16^INK4a and p15^INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood. 2001; 98:244–246. PMID: 11418489.

12. Guzman LM, Koriyama C, Akiba S, Eizuru Y, Castillo D, Corvalan A, et al. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile. Biol Res. 2007; 40:365–372. PMID: 18449464.

13. Dominguez G, Silva J, Garcia JM, Silva JM, Rodriguez R, Muñoz C, et al. Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res. 2003; 530:9–17. PMID: 14563526.

14. Tanaka R, Wang D, Morishita Y, Inadome Y, Minami Y, Iijima T, et al. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. Cancer. 2005; 103:608–615. PMID: 15612080.

15. Park G, Kang SH, Lee JH, Suh C, Kim M, Park SM, et al. Concurrent p16 methylation pattern as an adverse prognostic factor in multiple myeloma: a methylation-specific polymerase chain reaction study using two different primer sets. Ann Hematol. 2011; 90:73–79. PMID: 20721556.

16. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23:3412–3420. PMID: 15809451.

17. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20:1467–1473. PMID: 16855634.

18. Göhring G, Michalova K, Beverloo HB, Betts D, Harbott J, Haas OA, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010; 116:3766–3769. PMID: 20802024.

19. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93:9821–9826. PMID: 8790415.

20. Zheng S, Chen P, McMillan A, Lafuente A, Lafuente MJ, Ballesta A, et al. Correlations of partial and extensive methylation at the p14(ARF) locus with reduced mRNA expression in colorectal cancer cell lines and clinicopathological features in primary tumors. Carcinogenesis. 2000; 21:2057–2064. PMID: 11062168.

21. Martin P, Garcia-Cosio M, Santon A, Bellas C. Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol. 2008; 84:256–261. PMID: 18410922.

22. Ribas C, Colleoni GW, Felix RS, Regis Silva MR, Caballero OL, Brait M, et al. p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett. 2005; 222:247–254. PMID: 15863274.

23. Yuregir OO, Yurtcu E, Kizilkilic E, Kocer NE, Ozdogu H, Sahin FI. Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int J Lab Hematol. 2010; 32:142–149. PMID: 19302404.

24. Shiraz OB, Galehdari H, Yavarian M, Geramizadeh B. Possible down regulation of the p16 gene promoter in individuals with hepatocellular carcinoma. Hepat Mon. 2011; 11:719–723. PMID: 22235214.

25. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36:842–854. PMID: 1182674.

26. Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, et al. Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009; 23:1528–1534. PMID: 19322205.

27. Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19(Suppl 2):ii55–ii57. PMID: 18456769.